Chantelle Hudson

ORCID: 0009-0006-1179-7790
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer, Hypoxia, and Metabolism
  • Cancer Research and Treatments
  • Ovarian cancer diagnosis and treatment
  • Amino Acid Enzymes and Metabolism
  • Advanced Breast Cancer Therapies
  • Cancer-related Molecular Pathways
  • RNA modifications and cancer
  • Cancer Mechanisms and Therapy
  • CRISPR and Genetic Engineering
  • Microtubule and mitosis dynamics
  • DNA Repair Mechanisms
  • Bladder and Urothelial Cancer Treatments
  • Sulfur Compounds in Biology
  • MicroRNA in disease regulation
  • Radiopharmaceutical Chemistry and Applications
  • Molecular Biology Techniques and Applications
  • Glutathione Transferases and Polymorphisms
  • Retinal Diseases and Treatments
  • Pluripotent Stem Cells Research
  • Cancer Genomics and Diagnostics
  • RNA Research and Splicing
  • Receptor Mechanisms and Signaling
  • BRCA gene mutations in cancer
  • Down syndrome and intellectual disability research
  • Neuropeptides and Animal Physiology

BenevolentAI (United Kingdom)
2023-2025

Horizon Discovery (United Kingdom)
2017-2018

Case Western Reserve University
2016

Queen Mary University of London
2013-2014

Medical Research Council
2013

Cancer Research UK
2013

Southern Taiwan University of Science and Technology
2013

Wellcome Trust
2013

Cancer Genetics (United States)
2013

Barts Health NHS Trust
2013

Targeted therapies have yet to significant impact on the survival of patients with bladder cancer. In this study, we focused urea cycle enzyme argininosuccinate synthetase 1 (ASS1) as a therapeutic target in cancer, based our discovery prognostic and functional import ASS1 setting. expression status tumors from 183 Caucasian 295 Asian was analyzed, along its hypothesized association clinicopathologic features, including tumor size invasion. Furthermore, genetics, biology, implications loss...

10.1158/0008-5472.can-13-1702 article EN Cancer Research 2013-11-28

// Chantelle D. Hudson 1 , Alyssa Savadelis Anil Belur Nagaraj 2 Peronne Joseph Stefanie Avril 3 Analisa DiFeo 2, * Norbert 1, Department of Radiology, Case Center for Imaging Research, Western Reserve University, Cleveland, OH 44106, USA Comprehensive Cancer Center, Pathology, Shared senior authors Correspondence to: Avril, email: Norbert.Avril@Case.edu Keywords: ovarian cancer, cisplatin resistance, glutamine metabolism, glutaminase inhibitors Received: February 13, 2016 Accepted: April...

10.18632/oncotarget.9317 article EN Oncotarget 2016-05-12

The Brn-3a POU transcription factor is associated with survival and the differentiation of sensory neuronal cells during development. mediates its effects either by direct regulation target genes or indirectly upon interaction proteins such as p53. differentially regulates p53-mediated gene expression modifies effect on cell fate. Here we show that, like Bax, antagonizes another proapoptotic target, Noxa, significantly reducing transactivation Noxa promoter This requires p53 binding site,...

10.1074/jbc.m408679200 article EN cc-by Journal of Biological Chemistry 2004-12-15

Abstract Up to 90% of high-grade serous ovarian cancer (HGSC) patients will develop resistance platinum-based chemotherapy, posing substantial therapeutic challenges due a lack universally druggable targets. Leveraging BenevolentAI’s AI-driven approach target discovery, we screened potential AI-predicted targets mapped unapproved tool compounds in patient-derived 3D models. This identified TNIK, which is modulated by NCB-0846, as novel for platinum-resistant HGSC. Targeting this compound...

10.1158/1535-7163.mct-24-0785 article EN cc-by-nc-nd Molecular Cancer Therapeutics 2025-01-28

<div>Abstract<p>Up to 90% of patients with high-grade serous ovarian cancer (HGSC) will develop resistance platinum-based chemotherapy, posing substantial therapeutic challenges due a lack universally druggable targets. Leveraging BenevolentAI’s artificial intelligence (AI)–driven approach target discovery, we screened potential AI-predicted targets mapped unapproved tool compounds in patient-derived 3D models. This identified TNIK, which is modulated by NCB-0846, as novel for...

10.1158/1535-7163.c.7749840 preprint EN 2025-04-02

Aging is the major risk factor for chronic disease development. Cellular senescence a key mechanism that triggers or contributes to age-related phenotypes and pathologies. The endothelium, single layer of cells lining inner surface blood vessel, critical interface between all tissues. Many studies report link endothelial cell senescence, inflammation, diabetic vascular diseases. Here we identify, using combined advanced AI machine learning, Dual Specificity Tyrosine Phosphorylation Regulated...

10.1016/j.mad.2023.111836 article EN cc-by Mechanisms of Ageing and Development 2023-06-08

AbstractAcute myeloid leukaemia (AML) is the most common acute in adults. Around 10-15% of individuals with recessively inherited Fanconi anaemia (FA) develop AML. FA one a group recessive syndromes characterized by excessive spontaneous chromosomal breakage which heterozygote carriers appear to display an increased risk cancer and there some indirect evidence that may also be at This suggests genes play role development AML wider context. To examine this proposition, further, we have...

10.1080/1042819021000009274 article EN Leukemia & lymphoma/Leukemia and lymphoma 2002-01-01

Abstract The Brn‐3a transcription factor is critical for survival and differentiation of sensory neurons derived from neural crest cells (NCC). Interaction with p53 results in differential effects on target gene expression, which profoundly affects fate neuronal cells. Here we demonstrate colocalization a subset Brn‐3a‐positive NCC‐derived fated the lineage. distinct morphology Brn‐3a/p53‐coexpressing suggested differentiated cell type, this was confirmed by marker NF‐160. Functional...

10.1002/jnr.20299 article EN Journal of Neuroscience Research 2004-11-05

Abstract Background Arginine is an important amino acid for tumor cell growth and development. Argininosuccinate synthetase 1 (ASS1) a key enzyme required biosynthesis of arginine. Preclinically, ASS1-deficient cells are particularly sensitive to arginine depletion, randomised trials exploring this strategy in progress hepatocellular carcinoma mesothelioma using the drug pegylated deiminase (ADI-PEG20). In study, we determined metabolic changes induced by ADI-PEG20 treatment panel bladder...

10.1158/1538-7445.am2013-1885 article EN Cancer Research 2013-04-01
Coming Soon ...